RxDoctor Payments Data

Charles Ciolino, MD

Psychiatry · Summit, NJNPI 1841393121

Payments from drug & device makers

$8,483in general payments, 2019–2025

Across 478 payments — averaging $17.75 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
  • Axsome Therapeutics, Inc.$804
  • Otsuka America Pharmaceutical, Inc.$728
  • Takeda Pharmaceuticals U.S.A., Inc.$709
  • Teva Pharmaceuticals USA, Inc.$564
  • plus $3K from 19 others

What the payments were for

  • Food & beverage$8,25297%
  • Education$2313%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,483 in reported general payments places this provider in the 90th percentile of 1,119 psychiatry providers in New Jersey.

See all psychiatry providers in New Jersey

Medicare billing

Part B allowed, 2024
$35,748
Medicare patients
64
Services billed
337

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrintellixVortioxetine Hydrobromide21$21,182
VyvanseLisdexamfetamine Dimesylate11$4,139
Bupropion XlBupropion Hcl79$1,920
Alprazolam223$1,660
Escitalopram Oxalate73$894
Clomipramine Hcl21$787
Clonazepam86$719
Zolpidem Tartrate73$686
Sertraline Hcl57$640
Lamotrigine38$499
Venlafaxine Hcl ErVenlafaxine Hcl46$497
Duloxetine Hcl22$479
Clozapine25$457
Lorazepam51$353
Trazodone Hcl30$324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse$709$25,32132 claims
Almatica Pharma LLCSertraline Hcl$124$64057 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,119 psychiatry providers in New Jersey.

Other psychiatry in Summit

See the full list for New Jersey

Where these figures come from

Is this you, or does something look wrong? →